Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03588936
Title Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Medical College of Wisconsin

hematologic cancer


Nivolumab + Tocilizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.